About Lipidor AB

Lipidor AB ( www.lipidor.se ) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.

About AKP02G2

The drug candidate AKP02G2, which is a modified version of AKP02, combines calcipotriol and betamethasone and is based on Lipidor’s patented AKVANO®-technology.
The purpose of a new Phase III study with AKP02 in the form of AKP02G2 is to show good therapeutic effect for the treatment of mild to moderate psoriasis on both body and scalp. Lipidor has chosen to compare the sprayable drug candidate AKP02G2 with Enstilar, which is a commonly prescribed preparation in foam form for topical treatment in this indication, and which contains the same combination of active substances as AKP02G2. To reach a larger patient population, the scalp, which is often affected, has also been included in the study. Psoriasis on the scalp can range from mild to severe scaling and cause varying degrees of itching.

About the Swedish Medical Products Agency’s scientific advice

The Swedish Medical Products Agency provides scientific advice to the pharmaceutical industry and other parties, to facilitate an open dialogue concerning the development of new medicines. The advice given is non-binding, neither for the MPA nor for the company.